Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 5, 2020

Primary Completion Date

August 4, 2020

Study Completion Date

August 18, 2020

Conditions
Chronic Renal Impairment
Interventions
DRUG

HSK3486

HSK3486,Initially 0.4 mg/kg was administered as a 1 minute bolus, followed immediately by a constant infusion dose of 0.4 mg/kg/h administered as a 30 minute infusion via infusion pump.

Trial Locations (1)

450052

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Sichuan Haisco Pharmaceutical Group Co., Ltd

INDUSTRY

NCT04142970 - Safety and Pharmacokinetics/Pharmacodynamics of HSK3486 in Patients With Impairment Renal Functions | Biotech Hunter | Biotech Hunter